Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter.
The report, out from financial news wire Bloomberg, said the California biotech “is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,